Completed PHASE3 INTERVENTIONAL 2-arm NCT00134420

Growth Hormone and Chromosome 18q- and Abnormal Growth

Growth Hormone Trial for Children With 18q- and Abnormal Growth

Sponsor: Genentech, Inc.

Conditions Growth Hormone Deficiency Loss of Chromosome 18q

Interventions Arginine and Clonidine Stimulation Testing Growth Factors Laboratory Testing Neuropsychological Testing Nutropin AQ

Updated 6 times since 2017 Last updated: Aug 4, 2016 Started: Feb 28, 2001 Primary completion: Jun 30, 2005 Completion: Jun 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00134420, this PHASE3 trial focuses on Growth Hormone Deficiency and Loss of Chromosome 18q and remains completed. Sponsored by Genentech, Inc., it has been updated 6 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
South Texas Veterans Health Care System
The University of Texas Health Science Center at San Antonio

Data source: The University of Texas Health Science Center at San Antonio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Antonio, United States